Currently Viewing:
Currently Reading
What We're Reading: Distinct T1D Endotypes in Children; DNA Testing for Hereditary Breast Cancer; AI Use in Healthcare
March 16, 2020 – AJMC Staff
Did Medicaid Expansion Impact Cancer Diagnosis Rates?
March 11, 2020 – Rachel Lutz
If Equal Treatment, Then Equal Outcomes for Black, White Patients With TNBC, Study Says
March 06, 2020 – Rachel Lutz
What We're Reading: Cancer Clinical Trials; Affordable Housing From CVS; Drug Developed via Artificial Intelligence
February 12, 2020 – AJMC Staff
First Nations Women of Canada Have Higher Diabetes Rates, Study Finds
February 11, 2020 – Gianna Melillo
This Week in Managed Care: January 3, 2020
January 03, 2020
What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer
January 02, 2020 – AJMC Staff
Government-Insured Patients With Breast Cancer Face a Higher Risk of Death
December 17, 2019 – Gianna Melillo
This Week in Managed Care: December 13, 2019
December 13, 2019

What We're Reading: Distinct T1D Endotypes in Children; DNA Testing for Hereditary Breast Cancer; AI Use in Healthcare

AJMC Staff
Children were found to exhibit distinct type 1 diabetes endotypes compared with older adolescents; DNA testing has shown to be beneficial but controversial when personlizing care for patients with breast cancer; artifical intelligence (AI) usage across healthcare.

Researchers Discover Distinct T1D Endotypes in Children

In a study published in Diabetologia, researchers found that children younger than 7 years diagnosed with type 1 diabetes have a different endotype from those diagnosed at 13 years or older. Reported on by MedPage Today, the study analyzed pancreas samples derived from the child participants, revealing distinct patterns of proinsulin localization that were not as evident in the older group. “Our results strongly suggest that type 1 diabetes exists as distinct conditions that segregate according to age at diagnosis and are distinguishable histologically,” said the study authors.


Personalizing Hereditary Breast Cancer Treatments by DNA Testing

As DNA testing use grows to examine potential hereditary risks in breast cancer, a piece published in the The Washington Post discusses how even though these tests have led to the detection of a significant number of cancer-causing mutations, they have also contributed to potentially unnecessary surgeries. Initially, only the BRCA1 and BRCA2 mutations were tested, but now 30 to 80 cancer genes can be examined at a time, which may or may not have distinguishable cancer risks.


Artificial Intelligence Innovations in Healthcare

The use of artificial intelligence (AI) has led to several innovations within healthcare, such as faster diagnosis, automated claims processing, and accelerated development by pharmaceutical companies, among other advancements reported in Forbes. Additionally, ethical AI—when AI is used correctly and ethically—allows for greater accountability, traceability, and sustainability, which can assist in defining which AI use cases are and are not acceptable.

Related Articles

JAMA Study Reports Potential for Using Insulin to Prevent T1DM in High-Risk Children
Noninvasive ctDNA Test Sensitive to Early-Stage Cancer
The Future of Care Management in the Age of Artificial Intelligence
Personalizing Breast Cancer: How Liquid Biopsy Testing for ctDNA, CTCs Can Promote Preventive Care
Sleep Disorders Common in Patients With T1D, Review Shows
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up